1-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)imidazolidin-2-one

Catalog No. :
ACBFHS901
CAS No. :
883738-26-9
Molecular Formula :
C16H23BN2O3
Molecular Weight :
302.18

IUPAC Name:1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)imidazolidin-2-one

1-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)imidazolidin-2-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)imidazolidin-2-one
IUPAC Name1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)imidazolidin-2-one
MDL No.MFCD28167658
Molecular FormulaC16H23BN2O3
Molecular Weight302.18
SMILESO=C1NCCN1CC2=CC=CC(B3OC(C)(C)C(C)(C)O3)=C2
InChI KeyOVVJVGUNEKQSNA-UHFFFAOYSA-N
Synonym1-[3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-imidazolidin-2-one;2-Imidazolidinone, 1-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]-
CAS No.883738-26-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACBFHS901 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQJRP834 route compound structure diagram
    ACQJRP834214360-74-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBFHS901 route product structure diagram
    ACBFHS901883738-26-9
Inquiry

2. ACBFHS901 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBFHS901 route product structure diagram
    ACBFHS901883738-26-9
Inquiry

Comments (0)